Skip to main content
. 2005 Sep;79(17):11533–11536. doi: 10.1128/JVI.79.17.11533-11536.2005

FIG. 2.

FIG. 2.

(A) Hemagglutination assay of virus-like particles (VLPs) using unmodified (left) and VCNA-treated CRBCs (right). In both panels the top row corresponds to two hemagglutination units and the bottom row is a 1:2 dilution. (B) Hemagglutination assay of virus-like particles (VLPs) using CRBCs. The left panel shows SAα2,3Gal-resialylated CRBCs hemagglutinate VLPs expressing the A/New York/1/18 and the 1918 “avian” HAs but not A/South Carolina/1/18 HA. The right panel shows SAα2,6Gal-resialylated CRBCs hemagglutinate VLPs expressing the A/South Carolina/1/18 and A/New York/1/18 HAs but not 1918 “avian” HA. The amount of VLPs expressing the respective HAs was normalized with untreated CRBCs. In both panels the top row corresponds to two hemagglutination units and the bottom row is a 1:2 dilution. Production of SAα2,3Gal CRBCs was carried out in a 10% suspension with 0.5 mU of α2,3-(N)-sialyltransferase (Calbiochem) using 1.5 mM CMP-sialic acid in 50 μl for 2 h at 37°C. Production of SAα2,6Gal CRBCs was carried out in a 10% suspension with 1.0 mU of α2,6-(N)-sialyltransferase using 1.5 mM CMP-sialic acid in 125 μl for 2 h at 37°C.